Quantity of qualified sufferers: CDEC talked over the uncertainty in the number of sufferers with moderately serious to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients who will be classified as obtaining delicate or moderate illness might have a serious https://hemgenix73825.blogunteer.com/34685780/the-best-side-of-hemgenix